Lund University researchers developed a blood test aimed at identifying early indicators of breast cancer recurrence by detecting circulating tumor DNA fragments before conventional imaging or symptoms. The approach is positioned for earlier surveillance, potentially tightening the timeline from molecular signal to clinical evaluation. As oncology programs increasingly incorporate liquid biopsy tools, the emphasis in this work is on recurrence detection sensitivity—moving from post-treatment monitoring to earlier warning signals. If clinically validated, the test could support more responsive follow-up strategies for patients at risk of relapse.